Ulcerative Colitis (UC) - Epidemiology Forecast - 2032

Key Highlights

• Ulcerative Colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers on the inner lining of the large intestine (colon).
• Total diagnosed prevalent cases of Ulcerative Colitis in the 7MM range from ~3,012,740 in 2022 to ~4,176,530 in 2032.
• Severity-specific Ulcerative Colitis is classified into two subtypes: mild and moderate to severe. In the 7MM, the mild and total moderate to severe Ulcerative Colitis diagnosed prevalent cases were ~1,205,100 and 1,988,410 in 2022, which are likely to increase to ~1,670,610 and ~2,756,510, respectively, by 2032.
• in the United States, age-specific diagnosed prevalent cases of Ulcerative Colitis were ~43,129, ~862,577, 373,783, ~143,763, and ~14,376 in 2022, which are likely to increase to ~61,708, 1,234,160, 534,800, 205,693, and 20,569 in 0-17, 18-44, 45-64, 65-84, =85 years, respectively
• in the United States, total treated cases were ~575,051, ~853,951, ~264,725, and ~90,006 in 2022, which are likely to increase to 822,774, 1,221,819, 378,764 and 128,780, in mild, moderate-to-severe first line, moderate-to-severe second line, moderate-to-severe third line, respectively.

This “Ulcerative Colitis - Epidemiology Forecast - 2032” report delivers an in-depth understanding of Ulcerative Colitis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Ulcerative Colitis Understanding and Diagnostic Algorithm

Ulcerative Colitis Overview

Ulcerative colitis is an idiopathic inflammatory bowel condition; whose exact cause remains unknown. It affects the colonic mucosa and is characterized clinically by diarrhea, stomach discomfort, pain, and hematochezia. The extent of the disease is variable and may include either the rectum (ulcerative proctitis), the splenic flexure of the left side of the colon, or the whole of the rectum and bowel.

There are five types of ulcerative colitis: ulcerative proctitis, proctosigmoiditis, left-sided colitis (also limited or distal colitis), pancolitis, and extensive colitis. Based on severity, it can be classified as mild ulcerative colitis, moderate ulcerative colitis, and severe ulcerative colitis. Approximately 40% of people generally develop mild disease, and 60% develop moderate to severe disease at diagnosis.

It affects the colonic mucosa and is characterized clinically by diarrhea, stomach discomfort, pain, and hematochezia. The extent of the disease is variable and may include either the rectum (ulcerative proctitis), the splenic flexure of the left side of the colon, or the whole of the rectum and bowel.

Outside the gut, ulcerative colitis may cause problems. Some study indicates that as many as one in two individuals with ulcerative colitis can experience disorders that affect other parts of their body, such as the joints, eyes, or skin. Typically, these occur during a flare-up but can occur during remission or even before gut symptoms appear.

Ulcerative colitis diagnosis

Ulcerative colitis diagnosis is based on medical history, clinical judgment, serological observations, and findings. Ulcerative colitis patients may be identified by degree of disease, severity of disease, age of onset, extra-intestinal symptoms, and genetic markers. Before diagnosis, infective, ischemic, and irradiation causes of colitis must be excluded. The diagnosis of ulcerative colitis relies on (a) bloody diarrhea with negative stool cultures and (b) endoscopic evidence of diffuse, continuous mucosal inflammation involving the rectum and extending to a point more proximal in the colon. However, a commonly accepted catalog of well-defined criteria or a point score for the classification of ulcerative colitis does not exist.

Over the past decade, since the publication of the last guideline from the American College of Gastroenterology (ACG) on this topic, the management of the disease has grown increasingly complex with the availability of additional therapeutic classes. In addition, algorithms for initiating, optimizing, and monitoring responses to existing therapies have undergone considerable evolution. The diagnosis of ulcerative colitis should be suspected in patients with hematochezia and urgency. Infectious etiologies should be excluded at the time of diagnosis. Colonoscopy with intubation of the ileum and biopsies of affected and unaffected areas should be obtained to confirm the diagnosis of ulcerative colitis by a trained pathologist with expertise in gastrointestinal pathology when possible. Stool testing is recommended to rule out Clostridioides difficile in patients suspected of having ulcerative colitis (strong recommendation, very low quality of evidence)

Ulcerative colitis Epidemiology

As the market is derived using the patient-based model, the Ulcerative Colitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Ulcerative Colitis, Age-specific Cases of Ulcerative Colitis, Severity-specific Cases of Ulcerative Colitis, and Total Treated Patients of Ulcerative Colitis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032. The total diagnosed prevalent cases of Ulcerative Colitis in the 7MM comprised approximately 3,012,700 in 2022 and are projected to increase during the forecasted period.

• In the United States, the total number of diagnosed prevalent cases of ulcerative colitis was 1,437,600 in 2022.
• The United States contributed to the largest diagnosed prevalent population of ulcerative colitis, acquiring ~47% of the 7MM in 2022. In contrast, Germany and Japan accounted for around 10% each of the total 7MM population share in 2022.
• According to the publisher's estimates, the severity-specific diagnosed prevalent cases of Ulcerative Colitis were approximately 575,050 mild and 948,835 total moderate to severe cases in 2022 in the US. These cases are projected to increase during the forecasted period.
• In the 7MM, approximately 86% of the patient share is attributed to the 18-64 age group.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Ulcerative Colitis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

Ulcerative Colitis report insights

• Patient population
• Diagnosed Prevalence pattern
• Diagnosis rate
• Country-wise epidemiology distribution

Ulcerative Colitis Report key strengths

• Ten years forecast
• The 7MM coverage
• Ulcerative Colitis epidemiology segmentation

Ulcerative Colitis Report assessment

• Epidemiology segmentation
• Current diagnostic practices

Key Questions Answered

Epidemiology Insights

• What are the disease risk and burdens of Ulcerative Colitis? What will be the growth opportunities across the 7MM concerning the patient population of Ulcerative Colitis?
• What is the historical and forecasted Ulcerative Colitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why are only limited patients with symptoms treated?
• What factors are affecting the increase in the diagnosis of symptomatic cases?

Reasons to Buy

• The report will help develop business strategies by understanding the latest trends and changing epidemiology dynamics driving Ulcerative Colitis.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the perspective of Key Opinion Leaders around the current challenges with establishing the diagnosis and current diagnosis rate of the eligible patient pool.